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Cone/usions:The plaque comrmsition issimilarinmenand postmenopausal
women (-)E2 who have CAD. Plaque burden is less in postmenopausal
women (+) E2 and premenopeusal women (+) CAD wmpared to men and
postmenopausal women (–)E2. In postmenopausal women (+) E2, the %
stenosie is lees than postmenopausal women (-)E2. Estrogen is associated
with a decrease in Y. stenoeie and may favorably alter plaque composition in
postmenopausal women.
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T. Takegi, K. Yoshida, T. Akasaka, T. Hozumi, S. Morioka, J. Yoshikawa.
Kobe General Hospital, Kobe, Japan
To determine whather pravastatin reduces the progression of coronary
atherosclerotic plaque, 25 patients with elevated LDLchoresterol level 23.36
mmof/1were studied. The study patients were randomized into two groups:
prevastatin group, 13 patients w o
stabilization, and control group, 12 patients treated with diet stabilization
only. All patients underwent intravascular ultrasound (IVUS) studies before
and after the 3 yaare treatment period. IVUS images wera obtained in an-
giographicelly normal Coronary artery (% stenosis .c25%) ueing 4.3 F, XI
MHz IVUS catheter (CVIS) with motorized pullback (1.0 mrnkec). A cross
sectional image waa selected evey 1 see, and external elastic membrane
aree (EEM), lumen area (U), plaque area (PA= EEM – LA) ware measured
ueing computer planimetry and averaged over 10 framee. Results: There
wae no significant difference in LDL cholesterol level at baseline between
two groupe (4.6 + 0.5 mmolll in pravastatin group and 4.2 + 0.5 mmolil in
control group). LDLcholesterol reduction during treatment period waegreater
in prevastetin group than that in control group (26% vs 9%, respectively, p
< 0.005). There was no significant difference in plaque erea at baseline
betwean two groups (8.0 &2.7 mmz in pravastatin group and 7.3+ 1.9 mmz
in control group). Progression of the plaque area during treatment period
wae smaller in group than that in control group (-6% vs 41Y0,
respectively, p < 0.0005). Conclusion: Administration of pravastatin reduces
the progression of corona~ atherosclerotic plaque.
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M.J. Kern, T.J. Donohue, R.G. Bach, F.V.Aguirre, E.A. Careeciolo,
T.L. Wolford. Saint Louis University Health Sciences Center, St. Louis, MO,
USA
Post-stenotic coronafyflow resewe (CFR) represents the summed responee
of the conduit and microvaacularcirculation. CFR alone is not Ieeion-specific.
To aseeea intermediate left anterior descending and circumflex coronary
artery etenoaes with a Iesion-epecific meaauremant, intracoronary flow ve-
Ioeity resewe (CFR = adenosine hyperemiaheal mean flow velocity) was
measured with a 0.014 in. Flowire in a target (normal or etenotic) vessel
and an adjacent angiographieelly normal reference vessel. Relative CFR
wee computed aa CFR targetiCFR reference in 46 petienta with l-vessel
corona~ artery dieease and in 30 patients with normal left coronaty arteries.
Reaulta (mean+ SD).
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Relative CFR was related to percent diameter stenosie (r = 0.44; p =
0.0012). Concordance of CFR =. 2.0 in patients with normal vessels was
56/80 (90%). In patiants with l-vessel coronary artery disease, concordance
of CFR >2.0 was 23/’79 (29%).
These findings suggest that in patients with intermediate lesions, the
precision of post-stenotic CFR for lesion-specific flow impairment can be
improved using relativeCFR which utilizes an adjacent normal reference
vessel.
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J. Koyama, M. Owa, K. Asakawa, H. Hikita, K. Ohkubo, M. Shindo,
N. Yanagisawa. Shinshu University Matsumoto, Nagano, Japan
A variable degree of smooth muscle cell proliferation after balloon inju~ haa
been reported in enimal models. Although balloon angloplasty often dilates
non-stenotic coronary segments (NS) next to stenotic lesions in the clinical
settings, little is known about the influence of balloon dilation in NS. To clarity
the exietence of intimal proliferation in NS, intravascular ultrasound (IVUS)
was performed before and after balloon angioplasty and at remote phase
(after 3-S months) in 39 mrona~ segments from 22 patients. The lumen
area (LA), total vascular araa within the axfemal elastic Iamina (TA), and
plaque area (PA = TA – LA) were measured at NS and reference sites that
are not influenced by balloon dilation.
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Balloon dilation increaeed TA and PA significantly but did not change
LA. TA, LA and PA at reference sites were unchanged (p = N.S.). When
the degree of intimal proliferation was plotted against the distensibility of
coronary arteries ((post LA-pra LA)/pre IA), there was significant inverse
correlation (y = –0.678 x +33, r = 0.62, P < 0.05). Theee data suggest that
intimal proliferation occurs after balloon dilation in angiographically normal
segments and its response is proportional to the degree of balloon injury. If
vaecular distensibility is poor, the vessel wall will be damaged more severely.
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K, Jansson 1, K.-E. Karlberg2, E. Nylander’, E. Karlsson O. Nyqvist2,
U. Dahlstr6m. Linkdping Heart Centac Huddinge University Hospital,
Sweden, 2Linkc3pingUniversity Hespitaland Dept of Cardiology, Huddinge
University Hospital, Swedan
Objective.’Tostudy the effects of treatment with beta raceptor blockar (meto-
prolol) or an angiotensin-convetiing-enzyme inhibitor (captopril) on left ven-
tricular (LV)function in 53 patients with idiopathic dilated cardiomyopathy.
Method Cardiac cathetarisation was performed at rest and during supine
exercise before and after 3 months of treatment.
Resu/ts:Themean dose of metoprolol wae 135 mg perdayand of eapfopril
96 mg per day. Regarding left ventricular filiing pressure (PCW) and cardiac
output there was no differences between tha two groups at baseline. After
treatment there was a significant reduction in PCW both at rest (from 16 to
12 mm Hg) and during exercise (from 27 to 20 mm Hg) in the metoproiol
group. In the captopril treated patients there was no difference at rest but a
eignificent reduction was seen during exercise (25 to 20 mm Hg) compared
to baeeline. LVstroke volume (SV) was iowerat baseline in the group treated
with metoprolol than in the group traated with captopril (53versua 62 ml). The
SV increased significantly after 3 months of therapy in the metoprolol group,
both et rest (53 to 70 ml) and during exarcise (56 to 79 ml). In the ceptopril
group the increase reached significance only during exercise (72 to 79 ml).
Cardiac out-put was maintained in both groups. When comparing the change
from baseline, therapy with metoprolol reduced PCW at rest and increased
SV both at rest and during exercise significantly more than captopril did.
/n conclusion: Both treatments had positive effecte on LV function in
patients with dilated cardiomyopathy, but the effects of metoprolol were
greater,
